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Abstract
We investigated the antitumoral efficacy, endocrine
consequences, and molecular mechanisms underlying
cell death induced by the Hecate–chorionic gonadotro-
pin (CG)B conjugate, a fusionprotein of a 23–amino acid
lytic peptide Hecate with a 15–amino acid (81–95) frag-
ment of the humanCGB chain. Transgenic (TG)mice ex-
pressing the inhibin A-subunit promoter (inhA)/Simian
Virus 40 T-antigen (Tag) transgene, developing luteiniz-
ing hormone (LH) receptor (R) expressing Leydig and
granulosa cell tumors, and wild-type control littermates
were treated either with vehicle, Hecate, or Hecate–CGB
conjugate for 3 weeks. Hecate–CGB conjugate treatment
reduced the testicular and ovarian tumor burden (P <
.05), whereas a concomitant increase (testis; P < .05) or
no change (ovary) in tumor volumes occured with Hec-
tate treatment. A drop in serum progesterone, produced
by the tumors, and an increase in LH levels occured in
Hecate–CGB treated mice, in comparison with vehicle
and Hecate groups, providing further support for the
positive treatment response. Hecate–CGB conjugate in-
duced a rapid and cell-specific membrane permeabili-
zation of LHR-expressing cells in vitro, suggesting a
necrotic mode of cell death without activation of apop-
tosis. These results prove the principle that the Hecate–
CGB conjugate provides a novel specific lead into
gonadal somatic cell cancer therapy by targeted destruc-
tion of LHR-expressing tumor cells.
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Introduction
Early diagnosis and prevention of human gonadal tumors
remain difficult, which makes them a fatal group of malig-
nancies [1]. Although testicular tumors account for only 1%
of all tumors in males, they are the most common malig-
nancy inmen between 15 and 34 years of age [2]. Leydig cell
tumors are generally benign and account for about 2% of all
testicular tumors, withmalignancy occurring in about 10%of the
cases. If metastases are found, chemotherapy is the treatment
of choice because Leydig cell tumors are not radiosensitive [1].
Ovarian carcinoma is often called the ‘‘silent killer’’ because the
disease remains usually undetectable until the advanced
stage (II or IV) due to lack of diagnostic tests and absence of
solid symptoms [3,4]. Among ovarian tumors, those in granu-
losa cells are rare, accounting for 3.0% to 7.6% of primary
ovarian tumors. However, prospects of their treatment, in com-
parison to other ovarian cancers, are still poor [5,6]; tumor-
related mortality rate is 37.3% [3,7], and approximately 80% of
patients die of recurrent disease [7,8].
Themajor problems of cancer chemotherapies are related to
required therapeutic concentrations of drugs, exerting undesir-
able effects on normal cells and causing severe side effects [9].
The development of targeted antitumor drug delivery systems
has a great potential in enhancing chemotherapeutical efficacy
and specificity. Most of the lytic peptides produced by insects,
amphibians, and mammals have an amphipathic structure, and
they preferentially bind and insert into negatively charged cell
membranes [9]. In contrast to normal eukaryotic cells with low
membrane potential, the prokaryotic and cancer cell mem-
branesmaintain a largemembrane potential, and thereforemany
lytic peptides preferentially disrupt prokaryotic and cancer cell
membranes rather than those of healthy eukaryotic cells [10].
To eradicate cancer cells and to reduce the toxicity of
treatment toward normal tissues, we developed a novel ap-
proach for the treatment of endocrine tumors possessing
luteinizing hormone receptors (LHRs). We synthesized the
Hecate–chorionic gonadotropin b (Hecate–CGb) conjugate,
a fusion protein of the 23–amino acid membrane lytic peptide
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(Hecate) [11] and the 15–amino acid fragment of the human
CGb chain. The 81– to 95–amino acid region of CGb com-
poses the most potent region of the full-size CG protein
with important [12] roles in receptor binding [13]. We hypo-
thesized that the Hecate–CGb conjugate could serve as an
effective drug for the LHR expressed in gonadal tumors and
possibly for some nongonadal tumors [14,15]. The affinity of
the Hecate–CGb conjugate to LHR by targeted destruction
of LHR-expressing prostate, breast, ovarian, and testicular
cancer cell lines [16,17], and in prostate PC-3, ovarian
OVCAR-3, and breast MDA-MB-435S tumor xenografts
implanted in nude mice in vivo has been demonstrated
[16,18,19]. There are no existing reports wherein the thera-
peutic efficacy, endocrine, physiological, and pathophysio-
logical consequences of Hecate or Hecate–CGb conjugate
treatment been evaluated, with the use of a transgenic (TG)
preclinical model of tumorigenesis in a heritable immuno-
competent model of disease.
In the present study, we investigated the therapeutic
efficacy of the Hecate–CGb conjugate to eradicate LHR-
expressing tumor cells in vivo in a TG mouse model ex-
pressing the inhibin a-subunit promoter (inha)/Simian Virus
40 T-antigen (Tag) transgene and developing gonadal
tumors [20,21], as well as monitored the subsequent endo-
crine effects of the treatment as an indication of the thera-
peutic effect. We also investigated in vitro the susceptibility
of LHR-expressing tumor cells to Hecate–CGb conju-
gate treatment and addressed the mechanisms underly-
ing induced cell death, which has not yet been studied
or reported.
Materials and methods
Cell Lines and Cultures
The murine Leydig tumor cell line (mLTC-1) (LHR-
positive) [37] was cultured in Waymouth medium (Sigma
Chemical Co., St. Louis, MO), supplemented with 9% heat-
inactivated horse serum (Life Technologies, Paisley, Scot-
land, UK) and 4.5% heat-inactivated fetal calf serum (iFCS;
Bioclear, Wokingham, Berks, UK) containing 0.1 g/l genta-
micin (Gibco BRL, Gaithersburg, MD). Murine Leydig tumor
BLT-1 (LHR-positive) [20], murine granulose KK-1 (LHR-
positive) [21], prostate cancer PC-3 (LHR-positive) [38], and
colon carcinoma HT-29 (LHR-negative) [39] cells were
maintained in DMEM/Ham’s F-12 1:1 medium (Sigma),
supplemented with 10% iFCS, 50 IU/l penicillin, and 0.5 g/l
streptomycin (Sigma). The cells were allowed to grow on
9.6-cm–diameter Petri dishes (Greiner Labortechnik, Fricken-
hausen, Germany), or on 6- or 24-well plates (Greiner) to
70% to 80% confluency under a humidified atmosphere of
95% and 5% CO2 at 37jC.
Preparation of Drugs
Hecate and the Hecate–CGb conjugate were synthe-
sized and purified in the Peptide and Protein Laboratory,
Department of Virology, Hartman Institute, University of
Helsinki (Helsinki, Finland) as described earlier [29].
Experimental Animals
TG mice of 5.5 months age, expressing the inha/SV40
Tag transgene [40,22], all possessing macroscopic gonadal
tumors, were selected for the experiment (7–10 mice per
group). Wild-type (WT) littermate mice (C57Bl) were used as
controls (n = 4–7 per group). For routine genotyping, PCR
analyses were carried out using DNA extracts from tail
biopsies, as previously described [21]. Mice were housed
two to four per cage, after weaning at the age of 21 days, in a
room with controlled light (12 hours of light, 12 hours of
darkness) and temperature (21 ± 1jC). The mice were
specific pathogen-free and they were routinely screened
for common mouse pathogens. Avertin anesthesia was used
in surgical operations and postoperative analgesia (bupre-
norphine, 3 mg/mouse, by intraperitoneal injections) was
administered on a routine basis. The University of Turku
Ethical Committee on Use and Care of Animals approved
the animal experiments.
Hecate and Hecate–CGb Treatments
At the beginning of the experiment (at the age of
5.5 months), the gonadal size was assessed during lapa-
rotomy under general anesthesia, by measuring their length,
depth, and width. The product of these three measurements
(expressed in mm3) was taken as approximation of the total
gonadal volume, and the tumor volume burden was as-
sessed as total gonadal volume per gram of body weight.
Animals were treated with either vehicle or Hecate–CGb
conjugate (12 mg/kg) or Hecate (12 mg/kg) by intraperito-
neal injections. The mice were injected once per week for
three consecutive weeks, according to the earlier treatment
protocols for in vivo treatment for nude mice xenografts
[16,19,17]. Seven days following the last treatment, the mice
were sacrificed by cervical dislocation, and blood was col-
lected by cardiac puncture. Body, tumor, and different organ
weights were recorded. Tissues were either snap-frozen in
liquid nitrogen or fixed in Bouin’s solution or 4% paraformal-
dehyde, dehydrated, and embedded in paraffin. Paraffin
sections of 5 mm thickness were stained with hematoxylin/
eosin for histologic analysis.
Northern Hybridization Analysis
Total RNA was isolated fromWT and TGmice whole testis
or ovary (C; Hecate– and Hecate–CGb conjugate–treated
groups) using the single-step guanidinium thiocyanate–
phenol–chloroform extraction method [41]. Twenty micro-
grams of RNA per lane was resolved on 1.2% denaturing
agarose gel and transferred onto Hybond-XL nylon mem-
branes (Amersham International plc, Aylesbury, Bucks, UK).
Membranes were prehybridized overnight at 65jC in a solu-
tion containing 5 SSC, 5 Denhardt’s solution, 0.5% SDS,
50% formamide, and 5 g/l denatured calf thymus DNA. A
complementary RNA probe for the rat LHR generated from a
fragment of the LHR cDNA, spanning nucleotides 441 to 849
of its extracellular domain subcloned into the pGEM-4Z
plasmid, was used for hybridization [12]. The [32P]dUTP–
labeled (800 Ci/mmol; Amersham International) probe was
generated using a Riboprobe system II kit (Promega,
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Madison, WI). The probes were purified with NickColumns
(Pharmacia Biotech, Uppsala, Sweden). Hybridization was
carried out at 65jC for 20 hours in the same prehybridization
solution after the addition of labeled probe. After hybridization,
the membranes were washed twice in 2 SSC and 0.1% SDS
at room temperature for 10 minutes, followed by two washes
in 0.1 SSC and 0.1% SDS at 65jC to remove most of the
background. Finally, the membranes were exposed to Kodak
X-ray films (Kodak XAR-5; Eastman Kodak, Rochester, NY) at
70jC for 4 to 7 days, or to a phosphor imager (Fujifilm BAS-
5000; Fujifilm IaI, Tokyo, Japan) for 4 to 24 hours. The
intensities of specific bands were quantified using the Tina
software (Raytest, Staubenhardt, Germany) and related to
those of the 28S ribosomal RNA in the gel stained with
ethidium bromide. The molecular sizes of the mRNA species
were estimated by comparison with mobilities of the 18S and
28S ribosomal RNA.
Hormone Measurements
LH concentration in sera was measured by a supersen-
sitive immunofluorometric assay for rat LH (Delfia; Wallac
Oy, Turku, Finland) as described earlier [40]. Progesterone
was measured from diethyl ether extracts of the sera by
RIA as described earlier [42,43]. We took additional serum
samples (n = 7–8) from 6.5-month–old tumor-bearing inha/
Tag male and female mice treated with vehicle as controls for
hormone analyses.
Fluorescent Microscopy for PI Staining
To prove the preferential destruction of LHR-expressing
cells and to determine the mechanisms involved in cell
death caused by the Hecate–CGb conjugate, we cocultured
two cell lines, either murine Leydig mLTC-1 (LHR-positive)
and human colon carcinoma HT-29 cells (LHR-negative) or
murine granulosa KK-1 (LHR-positive) and human colon
carcinoma HT-29 cells (LHR-negative) (data shown only for
mLTC-1 and HT-29 cells), on the same glass well slides.
Because the cells differed markedly in their shape and size,
they were easy to distinguish. The cells were incubated for
24 hours in complete Waymouth medium, followed by a
wash with 1 PBS, and a further incubation in the presence
or absence of 0.5 mM Hecate or Hecate–CGb conjugate for
15 minutes. Thereafter, the medium was removed and
replaced with fresh medium containing PI, which does not
enter cells with intact membranes, and thus differentiates
between lysed and intact cells when studied by fluores-
cence microscopy. In the second set of experiments, we
treated mLTC-1 and HT-29 cells for 30 minutes with con-
centrations of 0.5, 1, and 5 mM Hecate. In the third set of
experiments, we treated mLTC-1 cells with 0.5 mM con-
centration of the Hecate–CGb conjugate for 0, 15, and
30 minutes.
FACS Analysis
Cells from two Leydig tumor cell lines, mLTC-1 and BLT-1
[20], and a prostate cancer cell line, PC-3, were seeded into
six-well plates in complete medium and incubated at 37jC in
5% CO2 for 24 hours. Cells were washed once with PBS and
then incubated for the next 4 hours at increasing concen-
trations (0.1, 0.5, and 1 mM) of Hecate or Hecate–CGb con-
jugate. As an apoptotic positive control, we used 0.1% of
hydrogen peroxide added to the culturemedia. Both adherent
and floating cells were collected and stained with PI, and cel-
lular DNA content was analyzed by FACSCalibur flow cyto-
meter (Becton Dickinson, Franklin Lakes, NJ) as previously
described [44,45].
Immunoblotting Analysis for Caspase-3 Activation
Western blotting analysis was used to determine whether
caspase-3 was activated with an antibody recognizing the
precursor and the active subunits. One day before stimula-
tion, mLTC-1 cells were plated on six-well plates at a den-
sity of 1.2  105 cells/well in 0.5 ml of complete Waymouth
medium. The cells were washed once with PBS and then
incubated for 60 minutes at 0.5, 1, and 5 mM Hecate or
Hecate–CGb conjugate. Total cell lysates were prepared as
described previously [46] and subjected to electrophoresis
through a 12.5% SDS-PAGE gel (60 mg protein/well). After
electrophoresis, proteins were electrotransferred to nitro-
cellulose membranes. After blocking the membrane, it was
incubated with the primary rabbit monoclonal antibody (Cell
Signaling, Beverly, MA). Signals were visualized using ECL
Plus Western blotting detection reagents (Amersham Phar-
macia Biotech, Buckinghamshire, UK) and finally exposed to
X-ray film.
Caspase Inhibitor Z-VAD.fmk
Cells were seeded into six-well plates at a density of 2 
105 cells/well. Twenty-four hours later, the medium was
replaced with new medium containing 20 mM pan-caspase
inhibitor Z-VAD.fmk (Calbiochem, Nottingham, UK) and in-
cubated for 1 hour. Hecate or Hecate–CGb conjugate was
then added at concentrations of 0.1, 0.5, and 1 mM and
incubated overnight. Incubation with the conjugate was
stopped after 16 hours. A colorimetric MTT assay was then
performed to measure cell survival [47]. We used 0.1% H2O2
as the positive control for apoptosis. Viability in the treated
cells was expressed as a percentage of controls. The
untreated controls were assigned a value of 100%.
Statistical Analysis
Statistical ANOVA paired t test analyses of variance were
carried out using a StatView program for Windows (version
5.0.1) (SAS Institute, Inc., Cary, NC). All data are presented
as the mean ± SEM.
Results
Hecate–CGb Treatment Reduced Tumor Volume
We were able to achieve an antineoplastic effect of the
Hecate–CGb conjugate on the inha/Tag TG mice. Here we
have used the same treatment strategy protocols used
earlier and established for in vivo xenograft treatments
[16,18,19]. Following 1-month treatment, total testicular
tumor volume decreased by an average of 58% (Figure 1a;
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P < .05; compared to the volume before treatment) and
that of the ovaries by 36% (Figure 1c). As the age-related
tumor progression rate was variable between animals,
which has been observed in the inha/Tag and Tag mice
before [22,20,21,23], we decided to show the tumor bur-
den, too. The gonadal tumor burden (i.e., tumor volume/g
body weight) after Hecate–CGb conjugate treatment in
both sexes decreased significantly in comparison with that
analyzed before treatment (Figure 1, b and d; P < .05). In
the Hecate-treated males, tumors grew steadily as in the
sham-treated control groups (Figure 1, a and b); but in fe-
males, the ovarian tumor volumes did not change signifi-
cantly (Figure 1, c and d ). Hecate–CGb conjugate and
Hecate treatments showed no significant influence on
gonadal volume in the WT mice group (Figure 1, a and c).
There were no statistically significant differences be-
tween the body weights among comparable groups (like
Hecate- or conjugate-treated, before and after the WT and
TG groups).
Hecate–CGb Treatment Was Specific Toward
LHR-Possessing Cells
To assess whether the Hecate–CGb treatment reduced
the LHR mRNA levels in comparison to Hecate- and sham-
treated TG control groups, wemade a quantitative evaluation
from RNA extracts of the total testes and ovaries of TG mice.
Northern hybridization revealed that there was a concomi-
tant decrease in LHR mRNA expression in the Hecate–
CGb–treated testes and ovaries (P < .01 and P < .05; versus
Hecate-treated groups and/or the sham-treated TG control
Figure 1. Total gonadal volumes of male (a) and female (c) wild-type (WT) control littermate mice and inha/Tag transgenic (TG) mice, before and after 3 weeks of
Hecate–CGb conjugate (Panels A), Hecate (Panels B), or sham treatment (Panel C). (b and d) Tumor burden volumes (tumor volume/g body weight). The values
are mean ± SEM of both gonads. *P < .05, Hecate, Hecate–CGb conjugate, or sham-treated gonadal volume after treatment versus before treatment. WT, wild-
type control littermate mice; TG, transgenic mice expressing the inhibina Simian Virus 40 T-antigen (inha/Tag).
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group) (Figure 2), which confirmed the LHR-specific destruc-
tion effects of Hecate–CGb and was in line with the reduced
tumor volume data (Figure 1).
Endocrine Consequences of Treatment
We have earlier shown that the serum progesterone
levels rise significantly and those of gonadotropins drop along
with tumorigenesis (6-month–old TG mice) in comparison
with WT control littermates [24,25]. After 3 weeks of treat-
ment with the Hecate–CGb conjugate, serum progesterone
concentration decreased significantly both in females and
males (Figure 3A; P < .05; versus Hecate-treated groups
and the sham-treated TG control group) and serum LH
concentration increased in the Hecate–CGb conjugate–
treated groups (Figure 3B; P < .01 to P < .05; versus
Hecate-treated groups and the sham-treated TG control
group). The hormonal values thus allowed us to monitor the
positive treatment effects of the Hecate–CGb conjugate.
Histopathologic Analysis Demonstrates Antitumoral Effect
of Hecate–CGb Conjugate Treatment
Histopathologic analysis showed that Hecate–CGb
conjugate treatment of TG mice induced a definite degra-
dation of testicular and ovarian tumor mass (more marked
in testis). In many parts of the histologic tumor sections, we
found clear changes in tumor tissues, apparently induced by
the treatment. Especially in testicular sections, a high num-
ber of neoplastic Leydig cells were destroyed, and the tumor
tissues apparently contained necrotic cells (Figure 4, B and
D). In contrast, in tissue sections collected from TG mice
Figure 1. (continued)
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treated with Hecate as well as in sham-treated TG mice
(data not shown), cell death appeared quite sporadically and
multiple mitoses were seen in the tumors (Figure 4, A and
C). The histologic results supported the data of reduced
tumor volumes in Figure 1. We studied the cross-sections of
several other organs (lungs, pancreas, liver, spleen, adre-
nals, and uterus) for posttreatment side effects or metas-
tases. Only in two males and one female treated with
Hecate or vehicle were lung metastases found, but never
in Hecate–CGb conjugate–treated groups. Histologic study
revealed no apparent effects of the treatments in extra-
gonadal organs (data not shown).
Mode of Antitumor Effect and Specificity of Selective
Cell Death
The preferential killing of LHR-expressing mLTC-1 Leydig
cells, but not of LHR-negative colon carcinoma HT-29 cells,
was clearly shown with the propidium iodide (PI) exclusion
experiment (Figure 5A). Nuclear PI staining showed that
15 minutes of 0.5 mM Hecate–CGb conjugate treatment
induced rapid permeabilization of the cell membrane and
killing of LHR-positive mLTC-1 cells, but not of HT-29 cells
(Figure 5A). Hecate treatment for 30 minutes at 1 mM con-
centration killed HT-29 cells only; but at 5 mM concentra-
tion, it killed both HT-29 and mLTC-1 cells (vs 0.5 mM
Hecate–CGb conjugate, killing mLTC-1 cells; Figure 5A)
with similar efficacy, regardless of the LHR expression
(Figure 5B). At 0.5 mM concentration, Hecate did not have
any effects on either cell line (Figure 5B). It has never been
shown earlier in such a simple but trivial way that the
Hecate–CGb conjugate selectively kills cells possessing
LHR but spares cells without LHR.
We analyzed further whether the molecular mode of
cell death induced by the Hecate–CGb conjugate could
be by necrosis. Light microscopic analysis revealed that
the moderate dose of 0.5 mM Hecate–CGb conjugate
for 30 minutes induced swelling of the mLTC-1 cells
(Figure 5C), indicating that the cells died as a result of
acute injury, swelling, and bursting, which strongly suggest
necrosis [26,27].
Further Studies on Molecular Mechanisms of the Selective
Death of LHR-Expressing Cells Induced by the
Hecate–CGb Conjugate
Flow cytometric analysis. The cells from all the three
cell lines (data shown only for mLTC-1 cells) treated with
Hecate or Hecate–CGb conjugate were lysed, cell nuclei
were stained with PI, and the percentage of cells undergoing
apoptosis by nuclear fragmentation was determined. The
percentage of cells undergoing apoptosis in the presence
of H2O2 was 62.4%, 53.6%, and 88.8% for mLTC-1, BLT-1,
Figure 2. Northern hybridization analysis of LHR mRNA expression in
Hecate and Hecate–CGb conjugate– treated or sham-treated testicular
and ovarian tissues of inha/Tag transgenic (TG) males and females. Each
lane contains 20 mg of total RNA. The migration of the 28S and 18S rRNA
are shown on the left side of the LHR panel. The sizes of the different LHR
mRNA splice variants (in kb) are presented on the right. Two lanes for each
type of sample are depicted. One lane of WT male and female gonad mRNA
expression is shown on the right as a positive control for LHR mRNA. The
upper panel shows on the top the ethidium bromide (EtBr) staining of the 28S
rRNA for RNA loading control. The middle panel shows Northern hybridi-
zation for LHR mRNA. The lower panel shows the densitometric quan-
tification of the longest (7.0 kb) LHR mRNA splice variant (open bar for
Hecate and filled bars for sham-treated and Hecate–CGb– treated) in
arbitrary densitometric units (mean of TG sham-treated testis and ovaries
regarded as 100%) corrected for intensity of the 28S rRNA band. Each bar
represents the mean ± SEM of three independent experiments in dupli-
cates. **P < .01, *P < .05 (P < .01 and P < .05; Hecate–CGb– treated versus
Hecate-treated and/or sham-treated TG control group). TG, transgenic mice
expressing the inhibina Simian Virus 40 T-antigen (inha/Tag); TG-C, sham-
treated TG mice.
Figure 3. Serum progesterone (A) and LH (B) concentrations in inha/Tag
transgenic female and male mice after the 3-week treatment with either
Hecate, Hecate–CGb conjugate, or sham (TG-C). **P < .01, *P < .05 (P < .01
and P < .05; Hecate–CGb– treated versus Hecate-treated and/or sham-
treated TG-C control group). TG, transgenic mice expressing the inhibina
Simian Virus 40 T-antigen (inha/Tag); TG-C, sham-treated TG mice.
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and PC-3 cells, respectively (Figure 6). All three cell lines
challenged with increasing concentrations of Hecate–CGb
conjugate or Hecate (0.1, 0.5, and 1 mM) for 4 hours showed
lack of nuclear fragmentation (Figure 6).
Analysis of caspase-3 activation. Incubation of mLTC-1
cells with Hecate–CGb conjugate or Hecate at 0.5 mM
concentration for 90 minutes did not induce the activation
of caspase-3 when analyzed by Western blot analysis
(Figure 7). This treatment caused a decrease in cell viability
but no active form (17 kDa) of caspase-3 could be detected
(Figure 7). These data provide strong evidence that the
cell death occurred without the proteolysis of procaspase.
Next, to check whether any activation of the apoptotic
pathways had taken place while causing cell death by Hecate
or Hecate–CGb conjugate, we used the pan-caspase inhibi-
tor to pretreat theBLT-1 andmLTC-1 Leydig tumor cells. Both
BLT-1 and mLTC-1 cell viability showed similar decreased
levels after treatment with the Hecate–CGb conjugate, as it
was caused without the inhibitor pretreatment levels (results
not shown). The minimum concentration of the Hecate–CGb
conjugate leading to 50% cell death (EC50) was 0.1 mM for
mLTC-1 cells. The same concentration of the conjugate
decreased the viability of BLT-1 cells until 40%. In the
presence of 0.5 to 1 mM concentration of the conjugate and
pretreatment with the Z-VAD.fmk inhibitor, cell viability oscil-
lated between 50% and 40% for mLTC-1 cells and between
35% and 30% for BLT-1 cells (results not shown). The pres-
ence or absence of the Z-VAD.fmk inhibitor did not signifi-
cantly change Leydig tumor cell viability after the treatment of
the Hecate–CGb conjugate, but in the positive control for
apoptosis with 0.1%of H2O2, the presence of Z-VAD.fmkwas
able to block apoptosis significantly (50%) (results not
shown). These results further proved that the mode of cell
death caused by the Hecate or Hecate–CGb conjugate was
not apoptosis, but necrosis, as shown in Figure 5C.
Discussion
In the present study, we took advantage of the established
inha/Tag TG mouse model of gonadal somatic cell tumori-
genesis [20,28,21,24,23], where the pathophysiological
and endocrine responses induced by tumorigenesis are
well-known. This information allowed us to gain insight into
the specific endocrine and paracrine consequences of the
Hecate and Hecate–CGb conjugate treatments. Here, we
were able to demonstrate in TG mice that the targeted
treatment with the Hecate–CGb conjugate, apparently
through binding to LHR, brought about effective blockage
and/or reduction of tumor growth. Hecate–CGb conjugate
treatment was able to reduce the total gonadal tumor
volumes of inha/Tag mice, without causing any noticeable
side effects.
It has been previously shown that the Hecate–CGb
conjugate is able to bind specifically to target cell membrane
LHR [29], including LHR-expressing tumor cells [16,17]. The
higher killing efficiency of the Hecate–CGb conjugate of
Leydig versus granulosa cells may be due to a higher level
of LHR expression in the former cell types. In accordance,
the granulosa (KK-1) and Leydig (BLT-1) cell lines derived
from the inha/Tag mouse gonadal tumors expressed 9870 vs
36,000 binding sites per cell, respectively [20,21]. The
Figure 4. Histologic pictures of hematoxylin/eosin–stained ovarian granulosa (A and B) and testicular Leydig cell (C and D) tumors of inha/Tag mice treated with
Hecate (A and C) or Hecate–CGb conjugate for three consecutive weeks. Arrows indicate that the interstitial tissue (B and D) has dramatically shrunken after
Hecate–CGb conjugate treatment (the bar in panel A is 40 m; panels B–D have the same magnification as panel A).
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Leydig cell tumors with a higher number of LHR per cell were
more susceptible to the destructive action of the Hecate–
CGb conjugate, as shown by histopathologic analysis. We
did not observe any drug-related alterations in other organs
like the liver, kidney, or uterus. Besides the LHR expression
of the tumor cells, electrostatic interactions between nega-
tively charged tumor cell membranes and nontumor cells
may explain the specificity of the action [30]. Some in vivo
studies have shown that the specific anticancer activities
of some native and synthetic cationic lytic peptides (e.g.,
Hecate) occurred only when they were conjugated to hom-
ing domains and were quite limited [30,31]. Hecate might be
cytotoxic to prokaryotic [11] and eukaryotic [17] cells, but
only at much higher concentrations, and then to cell types
regardless of their LHR expression [29], as also shown in
this study.
In the inha/Tag TG mice, the onset of tumor formation
paralleled increased serum progesterone and decreased
gonadotropin concentrations, with the former apparently
originating from an increased number of progesterone-
secreting tumor cells in the ovary [28,24,25], indicating
that the tumors were endocrinologically active and able
to exert enhanced negative feedback effects on pituitary
function [24,25,23]. The steroidogenesis of Leydig BLT-1
and mLTC-1 cells was partly impaired because it did not
proceed beyond progesterone to testosterone [20]. How-
ever, progesterone was also able to exert negative feed-
back actions on gonadotropin secretion [24,25], which
explains the suppression of their secretion in male mice.
Hence, if the targeted antitumor therapy with the Hecate–
CGb conjugate kills Leydig and granulosa tumor cells, then
the elevated level of serum progesterone would decrease
and serum LH concentration would increase. Indeed, after
3 weeks of treatment with the Hecate–CGb conjugate, the
progesterone concentration was significantly decreased
in the inha/Tag mice and serum LH concentrations were
significantly elevated, as compared with the respective levels
of untreated tumor mice and those receiving Hecate. This
was considered a distinct sign of endocrine recovery from
the hormonally active tumorigenesis under the Hecate–CGb
conjugate treatment.
We finally wanted to investigate the molecular mecha-
nisms underlying the mode of action of the Hecate–CGb
conjugate, namely the mechanisms involved in targeted cell
death. The cytotoxic effect of most antitumor agents de-
pends on the induction of apoptosis in susceptible tumor
cells [32]. Apoptotic cell death is characterized by a series
of specific events including the activation of the caspase
cascade, cell shrinkage, cell membrane blebbing, and
condensation and fragmentation of chromatin [33]. There
is evidence that the sensitivity of various tumor types to
current therapeutic methods depends on the activation of
multiple apoptosis-regulatory proteins [33,31,34]. There is a
preliminary report showing the involvement of phospholi-
pase PKC rather than PKA (PKC increased the sensitivity
to the drug) in breast cancer cell lysis by lytic peptide
hecate [19], although it has been also shown that PKC
activation can be antiapoptotic, too [35,36]. In this study,
two types of cocultured cell lines with or without endoge-
nous LHR treated with Hecate–CGb proved the high speci-
ficity for the LHR-expressing cells only, which has not been
shown earlier so precisely. The chain of events showed that
the binding of the Hecate–CGb conjugate to the LHR and
the rapid (within 15 minutes of PI administration) perme-
abilization and perturbation of cell membrane were the
cause of cell death. It seems that once the membrane
layer integrity is disturbed, which happens rapidly within
minutes, the transmembrane electrochemical potential col-
lapses and cell death occurs. Cell viability measurements
and fluorescence microscopic observations verified that the
cells died as a result of injury, swelling, and bursting, sug-
gesting signs of mechanisms of induction of necrosis, which
also has never been shown before. All attempts to dem-
onstrate apoptosis as a result of the treatments yielded
negative results.
Taken together, the present data provided strong evi-
dence for a rapid and specific killing mechanism by the
Hecate–CGb conjugate toward LHR-expressing gonadal
tumor cells through necrotic plasma membrane disrup-
tion. Cancer cells commonly have impaired/deleterious or
mutated genes involved in apoptosis, making them often
apoptosis-resistant. Therefore, the specific targeted necro-
sis induced by the Hecate–CGb conjugate for cancer cells
may offer an advantage and assure that the neoplastic
cells would not develop drug resistance to destructive
mechanism. Our in vivo results demonstrate that the
targeted therapy of gonadal somatic cell tumors expressing
LHR by the Hecate–CGb conjugate is potentially useful
and worthy of further testing, with potential for future
human trials.
Figure 5. Fluorescent and light microscopic analysis of cocultured Leydig tumor mLTC-1 (LHR-positive, bigger cells) and colon carcinoma HT-29 (LHR-negative,
smaller cells) (marked with arrows). (a) Pretreated with 0.5 M Hecate–CGb conjugate for 15 minutes in the presence of nonpermeable PI in the media. The left
panels (A and B) showed the light microscopic pictures of two different cell mixtures. The upper and lower middle darker field panels (C and D) showed PI
fluorescent microscopy. The cell membranes of the mLTC-1 cells were preferentially perturbed by the Hecate–CGb conjugate. Panels E and F are merged pictures
of light and PI fluorescent microscopy (the bar in panel A is 40 m; panels B–F have the same magnification as panel A). PI, propidium iodide. (b) Pretreated for
30 minutes with an increasing dose of Hecate: (A and D) 0.5 M, (B and E) 1 M, and (C and F) 5 M Hecate in the presence of nonpermeable PI in the media. The
left panels (A–C) show the light microscopy pictures. The right darker panels (D–F) show PI fluorescent microscopy. Hecate killed both mLTC-1 cells and HT-
29 cells with the highest (5 M) concentration used not depending on their LHR content. A concentration of 1 M Hecate killed only HT-29 cells (the bar in panel A
is 40 m; panels B–F have the same magnification as panel A). PI, propidium iodide. (c) Light microscopic picture of a single mLTC-1 Leydig tumor cell incubated
in 0.5 M Hecate–CGb conjugate for 0, 15, and 30 minutes. Cell swelling could be observed at 30 minutes (C), which strongly suggests necrosis as the mode of
cell death (the bar in the panel A is 40 m; panels B–C have the same magnification as panel A).
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Figure 6. Flow cytometric analysis of mLTC-1 cells treated for 4 hours with concentrations of 0.1, 0.5, and 1 M Hecate–CGb conjugate or Hecate. Cells treated
with 0.1% H2O2 for 4 hours were used as positive apoptotic controls. After incubation, cells were lysed in a hypotonic solution containing nonpermeable PI and
analyzed by FACS (FACSCalibur flow cytometer; Becton Dickinson). Neither Hecate–CGb conjugate nor Hecate treatment induced nuclear fragmentation in
mLTC-1 Leydig cells. The numbers on the top left quadrant of the panels represent the percentage of apoptotic cells. The data are representative of three separate
experiments with similar results.
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